PTH And Calcium Responses to Exercise (PACE) in Older Adults
12 mars 2018 mis à jour par: University of Colorado, Denver
Exercise that causes a decline in serum Calcium (Ca) as a result of dermal Ca loss stimulates bone resorption via an increase in Parathyroid Hormone (PTH).
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Determine whether the magnitude of dermal Ca loss (i.e., sweating) during exercise is a determinant of the decline in iCa and increases in PTH and carboxy-terminal collagen crosslinks (CTX; marker of bone resorption).
The proposed experiment will address this by manipulating the rate of dermal Ca loss (moderate vs high sweating rate) to determine whether this is the trigger for the cascade described in Figure 1.
This will be achieved by having participants perform two identical exercise bouts under different thermal conditions (warm vs cool).
Type d'étude
Interventionnel
Inscription (Réel)
12
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Hospital
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
60 ans à 80 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Healthy adults aged 60-80 y
Exclusion Criteria:
- Use of medications in the past 6 months known to affect bone metabolism (e.g., bisphosphonates, thiazide diuretics, oral glucocorticoids)
- BMD t score < -2.5 at the total hip or lumbar spine
- Known disease or condition associated with intestinal malabsorption
- Moderate or severe renal impairment defined as an estimated glomerular filtration rate of <60 mL/min/1.73m2 based on the MDRD equation
- Chronic hepatobiliary disease, defined as liver function tests (AST, ALT) >1.5 times the upper limit of normal; if such values are obtained on initial screening and thought to be transient in nature, repeated testing will be allowed
- Thyroid dysfunction, defined as an ultrasensitive TSH <0.5 or >5.0 mU/L; volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement
- Serum calcium <8.5 or >10.3 mg/dL
- Serum 25(OH)D <20 ng/mL; volunteers with abnormal serum 25(OH)D values may be re-considered for participation in the study if serum 25(OH)D is >20 ng/mL after vitamin D supplementation
- Uncontrolled hypertension defined as resting systolic BP >150 mmHg or diastolic BP>90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the PCP with initiation or adjustment of anti-hypertensive medications
- History of type 1 or type 2 diabetes
- Cardiovascular disease; subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT) without follow-up evaluation will be cause for exclusion; follow-up evaluation must include diagnostic testing (e.g., stress echocardiogram or thallium stress test) with interpretation by a cardiologist
- Diagnosis or history of asthma
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Treadmill Exercise
2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
|
2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
|
|
Expérimental: Magnitude of Ca loss during Exercise at 26 degrees Celcius
Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
|
Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Parathyroid Hormone (PTH)
Délai: 60 minutes of exercise and 2 hours of recovery
|
PTH will be measured during baseline, throughout exercise, and during recovery at regular intervals.
We are looking to see how PTH changes over the course of the exercise and recovery period in both the warm and cool conditions.
We anticipate that PTH will be higher in the warm condition versus the cool.
We expect that men and women will respond similarly.
|
60 minutes of exercise and 2 hours of recovery
|
|
Change C-Telopeptide (CTX)
Délai: 60 minutes of exercise and 2 hours of recovery
|
CTX will be measured during baseline, throughout exercise, and during recovery at regular intervals.
We are looking to see how PTH changes over the course of the exercise and recovery period in both the warm and cool conditions.
We anticipate that CTX will be higher during exercise and recovery in the warm condition versus the cool.
|
60 minutes of exercise and 2 hours of recovery
|
|
Change in Serum Ionized Calcium (iCa)
Délai: 60 minutes of exercise
|
iCa will be measured during baseline, throughout exercise, and during recovery at regular intervals.
We are looking to see how PTH changes over the course of the exercise and recovery period in both the warm and cool conditions.
We expect that serum iCa will be higher in the cool condition versus the warm.
|
60 minutes of exercise
|
|
Change in Total Ca
Délai: 60 minutes of exercise
|
Total Ca will be measured during baseline, throughout exercise, and during recovery at regular intervals.
We are looking to see how PTH changes over the course of the exercise and recovery period in both the warm and cool conditions.
|
60 minutes of exercise
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Sarah J Wherry, PhD, University of Colorado, Denver
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 août 2015
Achèvement primaire (Réel)
1 juin 2017
Achèvement de l'étude (Réel)
1 janvier 2018
Dates d'inscription aux études
Première soumission
2 juin 2015
Première soumission répondant aux critères de contrôle qualité
8 juin 2015
Première publication (Estimation)
11 juin 2015
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
14 mars 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
12 mars 2018
Dernière vérification
1 mars 2018
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 15-0250
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .